Targeting C-reactive protein for the treatment of cardiovascular disease.
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Complement-mediated inflammation exacerbates the tissue injury of ischaemic necrosis in heart attacks and strokes, the most common causes of death in developed countries. Large infarct size increases immediate morbidity and mortality and, in survivors of the acute event, larger non-functional scars adversely affect long-term prognosis. There is thus an important unmet medical need for new cardioprotective and neuroprotective treatments. We have previously shown that human C-reactive protein (CRP), the classical acute-phase protein that binds to ligands exposed in damaged tissue and then activates complement, increases myocardial and cerebral infarct size in rats subjected to coronary or cerebral artery ligation, respectively. Rat CRP does not activate rat complement, whereas human CRP activates both rat and human complement. Administration of human CRP to rats is thus an excellent model for the actions of endogenous human CRP. Here we report the design, synthesis and efficacy of 1,6-bis(phosphocholine)-hexane as a specific small-molecule inhibitor of CRP. Five molecules of this palindromic compound are bound by two pentameric CRP molecules, crosslinking and occluding the ligand-binding B-face of CRP and blocking its functions. Administration of 1,6-bis(phosphocholine)-hexane to rats undergoing acute myocardial infarction abrogated the increase in infarct size and cardiac dysfunction produced by injection of human CRP. Therapeutic inhibition of CRP is thus a promising new approach to cardioprotection in acute myocardial infarction, and may also provide neuroprotection in stroke. Potential wider applications include other inflammatory, infective and tissue-damaging conditions characterized by increased CRP production, in which binding of CRP to exposed ligands in damaged cells may lead to complement-mediated exacerbation of tissue injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Heuristics may lead to bias or predictable and systematic cognitive errors, as described in Table 2.16,35”
From Artificial Intelligence and Surgical Decision-making. (2020) · cites this paper as [54]
Citations
Cites
PROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
MOLREP: an Automated Program for Molecular Replacement
Vagin, A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,714
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 3,503
Self-citationWHAT IF: A molecular modeling and drug design program
Vriend, G. (1990) · Journal of Molecular Graphics · doi:10.1016/0263-7855(90)80070-v · Cited by 3,469
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Self-citationThe integration of macromolecular diffraction data
Leslie, A. G. W. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905039107 · Cited by 1,341
The physiological structure of human C-reactive protein and its complex with phosphocholine
Thompson, D., Pepys, M. B., & Wood, S. P. (1999) · Structure · doi:10.1016/s0969-2126(99)80023-9 · Cited by 818
Self-citation
Cited by
Items 501–600 of 670
Fernández‐Robredo, P., Recalde, S., Hernández, M., Zarranz‐Ventura, J., Molins, B., Casaroli-Marano, R. P., Adán, A., Sáenz-de-Viteri, M., & García‐Layana, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01862 · Cited by 8
“One proposal for those at-risk populations has been the inhibition of monomeric-CRP for local treatment of vascular disease (48) and reduction of myocardial infarct size (49) in at-risk areas.”
BackgroundSheriff, A., Kunze, R., Brunner, P., & Vogt, B. (2023) · Biomedicines · doi:10.3390/biomedicines11082279 · Cited by 7
“With a PC-mimic, one has to consider the administration of a highly polar, small molecular compound with poor bioavailability and a rapid half-life in high molecular access [12,15,61].”
BackgroundVos, F. E., Manning, P. J., Sutherland, W. H. F., Schollum, J. B. W., & Walker, R. J. (2010) · Nephrology · doi:10.1111/j.1440-1797.2010.01329.x · Cited by 7
“In rats administration of human CRP to damaged myocardial tissue increases the infarction size.(37,39) Specific therapies that reduce CRP levels may result in an anti-inflammatory and cardioprotective effect and reduce long-term cardiovascular risks.”
BackgroundLate medical versus interventional therapy for stable ST-segment elevation myocardial infarction
Elmariah, S., Smith, S. C., & Fuster, V. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1056 · Cited by 7
mCRP-Associated Vascular Pathophysiology in Progression and Outcome of Intracerebral Hemorrhage
Șalari, G., & SLEVIN, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136195 · Cited by 6
“H) [51].”
Li, C., Yan, C., Di, S., Yu, X. W., Zhang, X., Jiang, Z., Liu, G., Zhang, R., Zeng, D., Liu, Y., et al. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117807 · Cited by 6
Clinical and biochemical predictors of late-outcome in patients after ischemic stroke
Bielewicz, J., Kurzepa, J., Kamieniak, P., Daniluk, B., Szczepańska-Szerej, A., & Rejdak, K. (2019) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/105927 · Cited by 6
“CRP is considered to be a possible target for IS treatment [36, 37].”
BackgroundSileem, A. E., Embarak, S., & Meleha, M. S. (2014) · Egyptian Journal of Chest Diseases and Tuberculosis · doi:10.1016/j.ejcdt.2014.07.001 · Cited by 6
Insulin and endothelial function: A brief review
Ahmed, I., & Goldstein, B. J. (2008) · Insulin · doi:10.1016/s1557-0843(08)80038-3 · Cited by 6
Inflammasjon og C-reaktivt protein ved hjerte- og karsykdom
Munk, P. L., & Larsen, A. I. (2009) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.08.0011 · Cited by 6
Immunoadsorption Techniques and Its Current Role in the Intensive Care Unit
Hamilton, P., Harris, R., & Mitra, S. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84890 · Cited by 8
Zhang, Q., Du, G., Lu, T., Guo, X., & Wei, Y. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166805 · Cited by 6
Study of C-Reactive Protein and Myocardial Infarction in the Indian Population
Shalia, K. K., Savant, S. S., Haldankar, V. A., Nandu, T. S., Pawar, P. P., Divekar, S., Shah, V. K., & Bhatt, P. (2011) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-011-0164-9 · Cited by 6
“Studies on animal models indicate that CRP might have a pathogenic role in vascular disease [13–15].”
Putting genome analysis to good use: Lessons from C-reactive protein and cardiovascular disease
Manace, L. C., & Babyatsky, M. W. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.09169 · Cited by 6
Rogowski, O., Shapira, I., Toker, S., Melamed, S., Shirom, A., Zeltser, D., & Berliner, S. A. (2007) · Biomarkers · doi:10.1080/13547500701455604 · Cited by 6
Zhang, M., Liu, Y., Liu, Z., Wang, J., Gong, M., Ge, H., Li, X., Yang, Y., & Zou, Z. (2019) · Scientific Reports · doi:10.1038/s41598-019-39388-8 · Cited by 6
Jupiter to Earth: CRP Promotes Atherothrombosis
Jialal, I., & Devaraj, S. (2009) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2009.edi · Cited by 6
Biomarkers of Inflammation in Heart Failure: From Risk Prediction to Possible Treatment Targets
Aimo, A., & Bayés‐Genís, A. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2771 · Cited by 6
C-Reactive Protein: An Overview
Vashist, S. K. (2013) · Journal of Basic & Applied Sciences · doi:10.6000/1927-5129.2013.09.64 · Cited by 5
Torzewski, J., Mattecka, S., Ries, W., Garlichs, C. D., Heigl, F., Fiedler, J., & Sheriff, A. (2023) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2023.1286710 · Cited by 5
Höglund, N., Andersson, J. S. O., Almroth, H., Tornvall, P., Englund, A., Rosenqvist, M., Jensen, S. M., & Boman, K. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.05.071 · Cited by 5
“The current evidence is inconclusive as to whether inflammation causes AF or if AF itself generates inflammation [19,20].”
BackgroundTang, X., Yuan, D., Zhu, P., Xu, N., Yao, Y., Wang, P., Chen, Y., Gao, L., Song, L., Yang, Y., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23900 · Cited by 5
“…the ability of CRP to activate complement and colocalization of CRP and complement in ruptured atherosclerotic plaques [49], to bind to leukocytes and endothelial cells, to cause both upregulation of adhesion molecules and decreased production of nitric oxide, and to induce atherosclerosis [50].”
BackgroundDiepenhorst, G. M. P., Ciurana, C. L. F., Padilla, N. D., Boekholdt, S. M., Krijnen, P. A. J., Lagrand, W. K., Niessen, H. W. M., & Hack, C. E. (2012) · PubMed · Cited by 5
Proteome changes in rat plasma in response to sibutramine
Choi, J. W., Joo, J. I., Kim, D. H., Wang, X., Oh, T. S., Choi, D. K., & Yun, J. W. (2011) · PROTEOMICS · doi:10.1002/pmic.201000664 · Cited by 9
“Proteomic analysis Category (i) Apo A-I k[20] k[28–30] m m Apo C-I k[21] NA m ND CRP m[36] m[37] m m Apo M m[27] NA m ND VDBP m[44] NA k k a1-III NA NA k ND”
BackgroundGenomic Strategies Toward Identification of Novel Therapeutic Targets
Kessler, T., & Schunkert, H. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_360 · Cited by 8
Li, R.-Y., Zhao, D.-L., Yu, J.-W., Wu, Y., Chen, X., Ge, H., Li, C., & Ju, S. (2023) · Clinical Radiology · doi:10.1016/j.crad.2023.01.004 · Cited by 5
New approaches to the concept of primary prevention of atherosclerosis
Ford, M. A., Allison, T. G., & Lerman, A. (2008) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-008-0008-y · Cited by 8
Khedkar, V. M., Arya, N., Coutinho, E. C., Shishoo, C. J., & Jain, K. S. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-628 · Cited by 5
“Human CRP and its complements increase final myocardial infarction size in experimental models thus, making it a therapeutic target for decelerating the atherosclerotic plaque build-up process (Ridker 2003; Pepys et al. 2006; Libby et al. 2002 and Lowe 2005).”
BackgroundHoda, E. M., Dina, M. A., Same, M. S., & Amr, T. S. (2016) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp2016.4655 · Cited by 6
“Therapeutic inhibition of C-reactive protein (CRP) by GSE is considered as a promising new approach to cardioprotective and myocardial infarction or to other inflammatory, infective and tissue damaging conditions characterized by increased CRP level (Pepys et al., 2006).”
BackgroundEPSTI1 polymorphisms are associated with systemic lupus erythematosus
Mo, J., & Chae, S. (2017) · Genes & Genomics · doi:10.1007/s13258-017-0515-x · Cited by 5
“ESR and CRP are the two most common measurements of systemic inflammation, although there has been debate regarding the accuracy and sensitivity of ESR and CRP in conditions such as SLE (Pepys et al. 2006; Suh et al. 2006; Vila et al. 2005).”
BackgroundDesigning better nano biosensors: Role of pore confinement of biomolecules
Brandigampala, S. M., Feikert, P., Vattipalli, K., & Prasad, S. (2011) · IEEE International Conference on Nanotechnology (IEEE-NANO) · doi:10.1109/nano.2011.6144552 · Cited by 4
Liu, G., Huang, L., Lv, X., Guan, Y., & Li, L. (2024) · Transplant Immunology · doi:10.1016/j.trim.2024.102070 · Cited by 4
Hot and bothered: C-reactive protein, inflammation and atherosclerosis
Wierzbicki, A. S. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02211.x · Cited by 4
Vamshikrishnapatel, K., Biswas, R., Kumar, V. L., & Ojha, V. S. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-085078 · Cited by 4
The correlation between tumor necrosis factor gene polymorphism and diabetic retinopathy
Wang, J., Xiuyan, W., Zhengxuan, J., Ning, B., Liu, H., & Liming, T. (2018) · Biomedical Research - India · doi:10.4066/biomedicalresearch.29-17-1898 · Cited by 4
“The animal research indicated that used angiogenin-1 could control the expression of tumor necrosis factor effectively, which was helpful to improve the prognosis of early diabetic retinopathy in rats [22-24].”
BackgroundBoas, U., Daoud, M., Meier, S., Olsen, T. H., Gehring, K., Mogensen, D. J., & Heegaard, P. M. H. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c00085 · Cited by 4
Pastorello, Y., Russo, A. P., Bănescu, C. V., Caprio, V. E., Gáll, Z., Potempa, L. A., Cordoș, B. A., Napoli, M. D., & SLEVIN, M. A. (2024) · Cureus · doi:10.7759/cureus.60682 · Cited by 5
“To date, two small molecules - 1,6-bis(phosphocholine)-hexane (1,6-bis PC) and C10M have been identified as effective dissociation inhibitors [5,6].”
BackgroundHigh Sensitivity C-reactive Protein and Cardiovascular Risk Prediction
Trpković, A., Stanimirović, J., Resanović, I., Otašević, P., Jevremović, D., Djordje, R., & Isenović, E. R. (2014) · Current Pharmaceutical Analysis · doi:10.2174/1573412910666140822003911 · Cited by 4
Complement and complement deficiencies
Clos, T. W. D., & Mold, C. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04404-2.10020-x · Cited by 10
van Rijn, B. B. (2008) · Utrecht University Repository (Utrecht University) · Cited by 5
C-Reactive Protein and Reendothelialization
Szmitko, P. E., & Verma, S. (2007) · Circulation Research · doi:10.1161/01.res.0000269683.67849.b1 · Cited by 4
An aptamer specifically targeting mCRP ameliorates experimental arthritis
Wang, Z., Xie, D., Zhu, P., Guo, J., Cao, C., Du, Y., Lü, A., & Liang, C. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.08.010 · Cited by 4
“However, this approach is limited by challenges such as short half-life and low binding affinity [69].”
Tegler, L. T., Nonglaton, G., Büttner, F., Caldwell, K. D., Christopeit, T., Danielson, U. H., Fromell, K., Gossas, T., Larsson, A. O., Longati, P., et al. (2011) · Angewandte Chemie · doi:10.1002/ange.201005059 · Cited by 3
Kinugasa-Taniguchi, Y., Tomimatsu, T., Mimura, K., Kanagawa, T., Shimoya, K., Murata, Y., & Kimura, T. (2010) · Reproductive Sciences · doi:10.1177/1933719110361379 · Cited by 3
“Thus, administration of human CRP to rats has been used as a model for the actions of endogenous human CRP in several literatures.(18,22) Following these literatures, we used ‘‘administration of human CRP to rats’’ as a model for the actions of endogenous human CRP.”
MethodInflammatory Cytokines and Cardiovascular Risk
Lowe, G. D. O., Welsh, P. I., Rumley, A., & Sattar, N. A. (2011) · Science Publishers eBooks · doi:10.1201/b11037-22 · Cited by 4
Kather, M., Zeller, J., Plattner, D. A., Breit, B., Kreuzaler, S., Krippner, G. Y., Peter, K., Eisenhardt, S. U., & Kammerer, B. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.122998 · Cited by 3
Hernández-Banqué, C., Jové-Juncà, T., Crespo‐Piazuelo, D., González-Rodríguez, O., Ramayo‐Caldas, Y., Esteve‐Codina, A., Mercat, M.-J., Bink, M. C. A. M., Quintanilla, R., & Ballester, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1250942 · Cited by 4
C-Reactive Protein in Patients with NSTEMI Acute Coronary Syndrome
Dubey, R., Dhakal, N., Das, B., Pandey, N., Baral, N., & Lamsal, M. (2013) · Journal of Universal College of Medical Sciences · doi:10.3126/jucms.v1i1.8416 · Cited by 3
“01 2 hexane], which produces smaller infarct sizes in rats.(7) Regardless of whether CRP plays a causal role in atherothrombosis, this biomarker has been proposed to be useful for improving CVD-risk prediction.”
BackgroundQvarnström, M., Janket, S., Nuutinen, P., Furuholm, J. O., & Meurman, J. H. (2007) · Clinical Oral Investigations · doi:10.1007/s00784-007-0114-3 · Cited by 3
“Consequently, easily obtained saliva samples might be used to assess patient risk similarly to what has been suggested to be the case with C-reactive protein in blood [10, 29].”
MethodJc, H., Corbin, R., Dosman, J. A., & Dekker, M. (2006) · Cited by 3
Garofolo, L., Ferreira, S. R. G., & Miranda, F. (2014) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/s0100-69912014000300006 · Cited by 4
A novel peptide inhibitor attenuates C-reactive protein's pro-inflammatory effects in-vivo
Jialal, I., Devaraj, S., Smith, G. J., Lam, K. S., & Kumaresan, P. R. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.047 · Cited by 3
Use of High-Sensitivity C-Reactive Protein for Risk Assessment
Campbell, C. Y., Musunuru, K., Mora, S., & Blumenthal, R. S. (2009) · Elsevier eBooks · doi:10.1016/b978-141605469-6.50017-2 · Cited by 4
Putra, S. E., Tyas, F. N. I., Hafizhan, M., Prabaningtyas, R. A. H. R., & Mirawati, D. K. (2020) · Smart Medical Journal · doi:10.13057/smj.v3i2.43779 · Cited by 6
C-reactive Protein—Marker of Inflammation or Future Therapeutic Target?
McGrath, E. E., Watt, V., & Anderson, P. B. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.176.6.624 · Cited by 3
C-reactive protein in diabetic kidney disease: A new therapeutic avenue?
Cai, J., & Dong, Z. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.026 · Cited by 2
Reinstadler, S. J., Kronbichler, A., Reindl, M., Tiller, C., Holzknecht, M., Oberhollenzer, F., Kaser, A., Gauckler, P., Stiermaier, T., Feistritzer, H., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.07.067 · Cited by 2
Cheng, Z., Abrams, S. T., Toh, J., Wang, S. S., Downey, C., Ge, X., Yu, Q., Yu, W., Wang, G., & Toh, C. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900962 · Cited by 3
“Pch is a natural ligand of CRP and has the strongest affinity among all known interacting partners of CRP (10).”
BackgroundAbdelsalam, H. M. (2021) · International Journal of Clinical and Experimental Physiology · doi:10.5530/ijcep.2021.8.2.18 · Cited by 2
Cardiovascular Disease and Inflammation
Jankowska, M., Lindholm, B., & Stenvinkel, P. (2023) · Springer eBooks · doi:10.1007/978-3-030-62087-5_23 · Cited by 2
Liu, Y., Yuan, X., He, Y., Bi, Z.-H., Li, S., Li, Y., Liu, Y.-L., & Miao, L. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1442275 · Cited by 2
“Some research has even suggested a protective effect on the heart by reducing CRP levels in rats (21).”
BackgroundC-reactive protein and cardiovascular disease: Weighing the evidence
Lowe, G. D. O., & Pepys, M. B. (2007) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-007-0012-x · Cited by 2
Self-citationSpecific Interaction of Phospholipid Polymer with C-reactive Protein
Goda, T. (2015) · Journal of Photopolymer Science and Technology · doi:10.2494/photopolymer.28.715 · Cited by 2
The Anti-Inflammatory and Antiatherogenic Effects of Insulin
Dandona, P., Chaudhuri, A., Ghanim, H., & Mohanty, P. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-141-3_5 · Cited by 2
“The CRP suppressive action of insulin may also contribute to significant reduction in the size of the infarct as the administration of CRP to rats undergoing an experimental myocardial infarct, increases the size of the infarct and the prior administration of synthetic molecules which bind CRP and thus prevent its act…”
BackgroundChopra, V., & Eagle, K. A. (2010) · Indian Journal of Medical Sciences · doi:10.4103/0019-5359.75934 · Cited by 3
Modulation of Biomarkers of Inflammation
Jialal, I., & Devaraj, S. (2009) · Elsevier eBooks · doi:10.1016/b978-141605469-6.50037-8 · Cited by 3
Inflammation in Chronic Kidney Disease
Kovesdy, C. P., & Kalantar‐Zadeh, K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0987-2.00013-3 · Cited by 4
Acute Phase Reactants and the Concept of Inflammation
Nieves, C. E. F., Cronstein, B. N., & Saxena, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00057-7 · Cited by 3
The role of medicinal chemistry in the drug discovery process
Beswick, P., & NAYLOR, A. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7020-4299-7.00009-3 · Cited by 2
Afsargharehbagh, R., Shariati, A., & Isfandyari, P. (2020) · Journal of Acute Disease · doi:10.4103/2221-6189.281319 · Cited by 2
Visual sensing of multiple proteins based on three kinds of metal nanoparticles as sensor receptors
Liu, L., Zhang, L., & Liang, Y. L. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111574 · Cited by 2
C-reactive Protein Apheresis in Acute Myocardial Infarction
Milosevic, M., Balint, B., Ilić, I., Dukuljev, N., & Otašević, P. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230310090601 · Cited by 2
INFLAMMATORY MARKERS AS NOVEL PREDICTORS OF CARDIOVASCULAR DISEASE
Welsh, P. I. (2008) · Enlighten: Theses (The University of Glasgow) · Cited by 4
Inflammation and ischemia-reperfusion injury in STEMI
Lechner, I., Reindl, M., Metzler, B., & Reinstadler, S. J. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132760 · Cited by 2
Association of Admission CRP Level with Short Term Outcome in Patients with Acute Ischemic Stroke
Masud, M., Amin, M. A., Hossain, A., Murshed, S. M., Karmaker, P. P., Islam, M. M. S. U., Sharifunnesa, & Rahman, A. A. (2024) · Bangabandhu Sheikh Mujib Medical College Journal · doi:10.3329/bsmmcj.v3i1.71915 · Cited by 1
“Pepys et al. 10 showed 29% of patients were in low CRP group, 35% of patients were in medium CRP group, 36% of patients were in high CRP group.”
BackgroundTargeted gadolinium-labeled gold nanoparticles for MR imaging of C-reactive protein
DomNwachukwu, N. I., Bailey, M. D., Luo, M., Schiff, J., Brotherton, A. R., Phillips-Sorich, B., Rivnay, J., & Meade, T. J. (2025) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2025.113195 · Cited by 1
Feng, X., Jiang, X., Gong, S., Liu, W., Yan, Q., Qi, H., Yu, L., Wang, X., & Peng, X. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s584396 · Cited by 1
“36,37 For the first time, we linked serum C1r and C8 levels not only to the Gensini score but also to clinical myocardial injury. cTnT remains the gold-standard biomarker for evaluating myocardial damage and prognosis in CHD. 38 In our cohort, both C1r and C8 exhibited significant positive…”
Zhao, C., Chen, R., Feng, R., Xu, X., Sun, H., Min, X., Yang, H., Chen, J., & Li, X. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1858524 · Cited by 1
Non-invasive Methods for Cardiovascular Risk Assessment in Asymptomatic Type 2 Diabetes Mellitus
Lee, J. I., & Son, H. S. (2009) · Korean Diabetes Journal · doi:10.4093/kdj.2009.33.4.267 · Cited by 1
Kim, E. N., Choi, J. S., Kim, C. J., Kim, S. R., Kim, K.-B., & Oh, S. J. (2021) · The Korean Journal of Thoracic and Cardiovascular Surgery · doi:10.5090/kjtcs.20.096 · Cited by 2
“[22] reported that they used 1,6-bis(phosphocholine)-hexane, which could bind and inhibit human CRP, to reduce myocardial infarction size.”
MethodMaru, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-1757-7_16 · Cited by 1
Napoli, M. D., Smith, C. J., Hopkins, S. J., Popa‐Wagner, A., Bugă, A. M., & SLEVIN, M. A. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1071-7_11 · Cited by 2
“In animal models, the inhibition of CRP ligand-binding capability by 1,6-bis(phosphocholine)-hexane abrogated the increase in infarct size and cardiac dysfunction in poststroke animals [ 144 ].”
BackgroundC‐Reactive Protein and its Pathophysiological Roles in Atherosclerosis
Fan, J., Zhang, J., & Chen, Y. E. (2015) · Atherosclerosis · doi:10.1002/9781118828533.ch20 · Cited by 3
Inflammatory Biomarkers in Ischemic Heart Disease
Bjerre, M. (2012) · InTech eBooks · doi:10.5772/33905 · Cited by 1
“A similar effect was later found by administration of a specific synthetic CRP-inhibitor, 1,6-bis(phosphocholine)-hexane, which reduced the infarct size and thus provided promising results for therapeutic inhibition of CRP (Pepys et al., 2006).”
BackgroundCardiovascular Disease and Inflammation
Stenvinkel, P., & Ritz, E. (2009) · Springer eBooks · doi:10.1007/978-0-387-78940-8_23 · Cited by 1
Lovejoy, J. C., & Sasagawa, M. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0094-8 · Cited by 1
Markers of Inflammation among Nigerian Periodontitis Patients
Adegoke, O. M. A. A. (2014) · Journal of Immunological Techniques in Infectious Diseases · doi:10.4172/2329-9541.1000127 · Cited by 1
“Recent findings show that patient with elevated levels of CRP have a higher risk of developing atherosclerosis and other cardiovascular diseases; CRP has been proven to exacerbate ischemic necrosis in a complement dependent fashion [14], and a bystander in atherogenesis [15].”
BackgroundYousaf, S., Ahmed, M. U. D., Asif, M., Yousaf, S., & Munir, S. (2016) · Occupational Medicine & Health Affairs · doi:10.4172/2329-6879.1000247 · Cited by 1
El‐Shoura, E. A. M., Messiha, B. A. S., Abo‐Youssef, A. M., & Hemeida, R. A. M. (2015) · Pharmaceutical and Biosciences Journal · doi:10.20510/ukjpb/3/i1/89218 · Cited by 1
Rozenbaum, Z., Ravid, D., Margolis, G., Khoury, S., Kaufman, N., Keren, G., Milwidsky, A., & Shacham, Y. (2018) · Biomarkers · doi:10.1080/1354750x.2018.1460765 · Cited by 1
“In the setting of MI, CRP-targeted therapeutics was demonstrated to be cardio-protective in animal models (Pepys et al. 2006, Sheriff et al. 2015).”
BackgroundMo, J., & Soo-cheon, C. H. A. E. (2018) · Archives of Rheumatology · doi:10.5606/archrheumatol.2018.6644 · Cited by 1
Targeting C-Reactive Protein in Inflammatory Disease
Zeller, J., & Eisenhardt, S. U. (2019) · Springer eBooks · doi:10.1007/978-3-030-19958-6_17 · Cited by 1
Relationship of Atherosclerotic Risk Factors with Pulmonary Age and Vascular Age
Shimizu, M., Okano, A., Adachi, M., & Maruyama, Y. (2019) · doi:10.11320/ningendockitn.6.1_3 · Cited by 1
Thoughts of an Immunobiologist about Covid-19
(2020) · doi:10.31038/idt.2020115 · Cited by 1
“CRP values are also importantly prognostic in many conditions, including Covid-19, consistent with CRP not merely reflecting disease activity but also acting as a pathogenic factor, as first demonstrated by Pepys [18].”
BackgroundChronic Microinflammation as “Friendly-Fire” in Aging and Disease
Endo, Y., Ninomiya, K., & Ooi, S. L. (2023) · Springer eBooks · doi:10.1007/978-981-19-5735-2_9 · Cited by 1
The impact of rosuvastatin on inflammatory markers in L-NAME induced hypertensive rats
Dizaye, K. F., & Berzinji, B. (2023) · Zanco Journal of Medical Sciences · doi:10.15218/zjms.2023.011 · Cited by 1
Stem Cell Therapy for Heart Failure Using Cord Blood
Patel, A. N., Sakthivel, R., & Ichim, T. E. (2010) · Springer eBooks · doi:10.1007/978-1-84882-718-9_23 · Cited by 1
Wennberg, P. (2009) · DiVA at Umeå University (Umeå University) · Cited by 2
Therapeutic potential of phosphoethanolamine-bound C-reactive protein in atherosclerosis
Agrawal, A. C. (2008) · Future Lipidology · doi:10.2217/17460875.3.6.599 · Cited by 1
Potential use of insulin as an anti‐inflammatory drug
Dandona, P., Chaudhuri, A., Ghanim, H., & Mohanty, P. (2008) · Drug Development Research · doi:10.1002/ddr.20233 · Cited by 1
“…of infarct size since the injection of CRP in experimental myocardial infarction has been shown to increase the size of the infarct [Griselli et al., 1999], and small molecules specifically synthesized to bind CRP and to block its action reduce the size of the infarct [Pepys et al., 2006].”
Background
Metadata
- Authors
- Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Ruth Gallimore, J., Kahan, M. C., Bellotti, V., Hawkins, P. N., Myers, R. M., Smith, M. D., Polara, A., Cobb, A. J. A., Ley, S. V., Andrew Aquilina, J., Robinson, C. V., Sharif, I., Gray, G. A., Sabin, C. A., Jenvey, M. C., Kolstoe, S. E., Thompson, D., & Wood, S. P.
- Affiliations
- The Royal Free Hospital (GB)
- University of Pavia (IT)
- University of Cambridge (GB)
- University of Edinburgh (GB)
- University of Southampton (GB)
- University of Sussex (GB)
- Corresponding author
- Pepys, Mark B.
- ORCID
- Venue
- Nature
- Published
- 2006-04
- Volume
- 440
- Issue
- 7088
- Pages
- 1217-1221
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2080883999
- Cited by
- 672
- References
- 31
- Citations by year
- 2026: 6 · 2025: 17 · 2024: 19 · 2023: 30 · 2022: 27 · 2021: 28 · 2020: 32 · 2019: 21 · 2018: 23 · 2017: 20 · 2016: 23 · 2015: 16 · 2014: 35 · 2013: 30 · 2012: 40
- FWCI
- 26.49
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- CentAUR (University of Reading) (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (submittedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- C-reactive protein, acute myocardial infarction, complement activation, cardioprotection, infarct size, neuroprotection, cerebral ischemia, small-molecule drug design, acute phase proteins, inflammation, stroke, drug repurposing
- MeSH terms
- Animals, C-Reactive Protein, Cardiovascular Diseases, Complement System Proteins, Hexanes, Humans, Male, Models, Molecular, Molecular Conformation, Myocardial Infarction, Phosphorylcholine, Drug Design, Rats, Wistar, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.